Anaptysbio (ANAB) Treasury Shares (2016 - 2026)
Anaptysbio's (ANAB) quarterly Treasury Shares came in at $1.4 million in Q1 2026, down 8.06% YoY from $1.5 million in Q1 2025, and up 191.72% on a QoQ basis from $478000.0 in Q4 2025.
Anaptysbio (ANAB) Treasury Shares (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 6 years of Treasury Shares data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Treasury Shares fell 8.06% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 8.06% YoY) and the FY2025 annual result came in at $478000.0, down 61.06% from the prior year.
- Treasury Shares advanced to $1.4 million in Q1 2026, from $478000.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $1.5 million in Q1 2025 to a low of $478000.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares soared 54.17% — and 2024, when it slumped 64.17%.
- Tracing ANAB's Treasury Shares over 5 years: stood at $1.0 million in 2022, then jumped by 44.0% to $1.5 million in 2023, then fell by 17.14% to $1.2 million in 2024, then tumbled by 61.06% to $478000.0 in 2025, then jumped by 191.72% to $1.4 million in 2026.
- The last three Treasury Shares figures came in at $1.4 million (Q1 2026), $478000.0 (Q4 2025), and $498000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 478,000.00 |
| Dec 31, 2025 | 478,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.52 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 511,000.00 |
| Sep 30, 2024 | 511,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |